Opus Genetics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Opus Genetics, Inc. (IRD) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $804.00K.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $432.00K, a 58.82% increase year-over-year.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$873.00K, a 137.09% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$946.00K, a 154.00% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$3.50M, a 161.59% decline from fiscal 2024.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $5.67M, a 4513.82% increase from fiscal 2023.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $123.00K.
- Opus Genetics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$51.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $804.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.24M 10-Q · filed 2026-08-06 | $363.00K derived: sum of 3 quarters · filed 2026-08-06 | -$583.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $432.00K 10-Q · filed 2026-05-12 | -$441.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.39M derived: sum of 3 quarters · filed 2026-05-12 | -$3.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$873.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.82M derived: sum of 2 quarters · filed 2026-03-12 | -$3.77M derived: sum of 3 quarters · filed 2026-08-06 | -$3.50M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$946.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.89M derived: sum of 2 quarters · filed 2026-08-06 | -$2.62M 10-Q · filed 2025-11-12 | -$268.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.68M 10-Q · filed 2026-08-06 | $678.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $272.00K 10-Q · filed 2026-05-12 | $2.63M derived: sum of 2 quarters · filed 2026-05-12 | $4.38M derived: sum of 3 quarters · filed 2026-05-12 | $4.22M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.11M derived: sum of 2 quarters · filed 2026-03-12 | $3.94M derived: sum of 3 quarters · filed 2026-03-12 | $5.67M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.59M derived: sum of 2 quarters · filed 2025-11-12 | $3.32M 10-Q · filed 2025-11-12 | $3.21M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.57M 10-Q · filed 2025-08-13 | $1.45M derived: sum of 3 quarters · filed 2025-08-13 | -$53.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.73M 10-Q · filed 2025-05-15 | $1.61M derived: sum of 2 quarters · filed 2025-05-15 | $108.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.61M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.62M derived: sum of 2 quarters · filed 2025-03-31 | -$124.00K derived: sum of 3 quarters · filed 2025-03-31 | $123.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$8.00K derived: sum of 2 quarters · filed 2024-11-12 | $239.00K 10-Q · filed 2024-11-12 | $700.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.75M 10-Q · filed 2024-08-13 | $2.21M derived: sum of 3 quarters · filed 2024-08-13 | $2.01M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $247.00K 10-Q · filed 2024-05-10 | $708.00K derived: sum of 2 quarters · filed 2024-05-10 | $514.00K derived: sum of 3 quarters · filed 2024-05-10 | $515.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $267.00K derived: sum of 2 quarters · filed 2024-03-08 | $268.00K derived: sum of 3 quarters · filed 2024-03-08 | -$51.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$193.00K derived: sum of 2 quarters · filed 2023-11-13 | -$512.00K 10-Q · filed 2023-11-13 | $100.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$318.00K 10-Q · filed 2023-08-11 | $294.00K derived: sum of 3 quarters · filed 2023-08-11 | $343.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$319.00K 10-Q · filed 2023-05-15 | $293.00K derived: sum of 2 quarters · filed 2023-05-15 | $342.00K derived: sum of 3 quarters · filed 2023-05-15 | $689.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $661.00K derived: sum of 2 quarters · filed 2023-03-30 | $1.01M derived: sum of 3 quarters · filed 2023-03-30 | -$155.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $396.00K derived: sum of 2 quarters · filed 2022-11-04 | -$767.00K 10-Q · filed 2022-11-04 | $462.00K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$816.00K 10-Q · filed 2022-08-12 | $413.00K derived: sum of 3 quarters · filed 2022-08-12 | $652.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$1.16M 10-Q · filed 2022-05-13 | $66.00K derived: sum of 2 quarters · filed 2022-05-13 | $305.00K derived: sum of 3 quarters · filed 2022-05-13 | $297.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $1.47M derived: sum of 2 quarters · filed 2022-03-24 | $1.46M derived: sum of 3 quarters · filed 2022-03-24 | $1.26M 10-K · filed 2022-03-24 |
| 2020-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $231.00K derived: sum of 2 quarters · filed 2021-11-12 | $31.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$208.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$200.00K 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $467.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |